Clinical trial · Observational
Efficacy and Safety of Camrelizumab in Real-World Study
Efficacy and Safety of Camrelizumab for Chinese NSCLC Patients: a Retrospective, Observational, Multicenter Real-World Study
NCT04631146CI-TRIAL-00048317unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This observational real-world study is designed to evaluate the efficacy and safety of camrelizumab for the treatment of Chinese NSCLC patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Camrelizumab | Drug | Camrelizumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Camrelizumab-treated advanced NSCLC
- description
- Patients with advanced non-small cell lung cancer treated with camrelizumab. Dosage form, dosage, frequency and duration of camrelizumab is determined according to the investigator's actual clinical practice.
- interventionNames
- Drug: Camrelizumab
Primary outcomes (4)
- measure
- pCR
- timeFrame
- From August 1, 2019 to June 31, 2021
- description
- Neoadjuvant therapy population: pathological complete response rate (pCR).
- measure
- R0 resection rate.
- timeFrame
- From August 1, 2019 to June 31, 2021
- description
- Neoadjuvant therapy population: R0 resection rate.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥18 years old; 2. Histopathological diagnosed confirmed non-small cell lung cancer; 3. Have received at least one camrelizumab injection between August 1, 2019 and December 31, 2020; 4. Traceable cases. Exclusion Criteria: 1. Patients who have received other immunotherapy at the same time; 2. Patients who were participating in other intervention studies; 3. Patients with other malignant tumors; 4. The researcher believes that the patient is not suitable to participate in this study with any other conditions .
References
Publications (0)
Data not yet available
No reference posted for this study.